Vir Biotechnology (VIR) Accumulated Depreciation (2018 - 2023)

Vir Biotechnology has reported Accumulated Depreciation for 6 years, with the latest figure at $26.2 million in Q1 2023.

• Quarterly Accumulated Depreciation rose 65.06% year-over-year to $26.2 million in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $26.2 million (up 65.06% YoY) and the FY2022 annual result came in at $20.7 million, up 43.13% from the prior year.
• Accumulated Depreciation improved to $26.2 million in Q1 2023 per VIR's latest filing, from $20.7 million in the prior quarter.
• Over five years, Accumulated Depreciation peaked at $26.2 million in Q1 2023 and troughed at $4.2 million in Q3 2019.
• A 5-year average of $12.5 million and a median of $11.8 million in 2021 frame the typical range for Accumulated Depreciation.
• The sharpest annual moves came in 2019 and 2022: Accumulated Depreciation soared 181.59% in 2019, then soared 43.13% in 2022.
• Over 5 years, Accumulated Depreciation stood at $4.8 million in 2019, then surged by 91.06% to $9.2 million in 2020, then jumped by 56.98% to $14.5 million in 2021, then surged by 43.13% to $20.7 million in 2022, then rose by 26.54% to $26.2 million in 2023.
• According to Business Quant data, Accumulated Depreciation over the past three periods registered $26.2 million, $20.7 million, and $18.9 million for Q1 2023, Q4 2022, and Q3 2022 respectively.